Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN),
TEN, Ltd (NYSE:TNP) (the "Company") announces that following the delivery of three vessels since the beginning of 2024, the Dual-Fuel LNG LR2 product tankers "Ithaki DF", "Chios DF" and "DF Montmartre", three more
Take-Two Interactive reported adjusted earnings of $1.21 per share and quarterly sales of $1.399 billion, beating the $1.299 billion analyst consensus estimate. Total Net Bookings decreased 3% to $1.35 billion, as compared to $1.39 billion from the prior year's fiscal fourth quarter.
HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular RejectionCardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive
Evoke Pharma, Inc.(NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that
Citron Research founder Andrew Left worked investors up after shorting GameStop in 2021. The short seller could see a similar reaction targeting the cryptocurrency sector.
Applied Materials said second-quarter revenue was flat on a year-over-year basis. The chip equipment company reported total revenue of $6.646 billion which beat the consensus estimate of $6.537 billion, according to Benzinga Pro. Applied Materials reported adjusted earnings of $2.09 per share, beating analyst estimates of $1.99 per share.